FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000603962> ?p ?o ?g. }

• W2000603962 endingPage "28949" @default.
• W2000603962 startingPage "28944" @default.
• W2000603962 abstract "Accumulating evidence has suggested that prion protein (PrP) is neuroprotective and that a PrP-like protein/Doppel (PrPLP/Dpl) is neurotoxic. A line of PrP-deficient mice, Ngsk Prnp0/0, ectopically expressing PrPLP/Dpl in neurons, exhibits late-onset ataxia because of Purkinje cell death that is prevented by a transgene encoding wild-type mouse PrP. To elucidate the mechanisms of neurodegeneration in these mice, we introduced five types of PrP transgene, namely one heterologous hamster, two mouse/hamster chimeric genes, and two mutants, each of which encoded PrP lacking residues 23–88 (MHM2.del23–88) or with E199K substitution (Mo.E199K), into Ngsk Prnp0/0 mice. Only MHM2.del23–88 failed to rescue the mice from the Purkinje cell death. The transgenic mice, MHM2.del23–88/Ngsk Prnp0/0, expressed several times more PrP than did wild-type (Prnp +/+) mice and PrPLP/Dpl at an equivalent level to Ngsk Prnp0/0 mice. Little difference was observed in the pathology and onset of ataxia between Ngsk Prnp0/0 and MHM2.del23–88/Ngsk Prnp0/0. No detergent-insoluble PrPLP/Dpl was detectable in the central nervous system of Ngsk Prnp0/0 mice even after the onset of ataxia. Our findings provide evidence that the N-terminal residues 23–88 of PrP containing the unique octapeptide-repeat region is crucial for preventing Purkinje cell death in Prnp0/0 mice expressing PrPLP/Dpl in the neuron. Accumulating evidence has suggested that prion protein (PrP) is neuroprotective and that a PrP-like protein/Doppel (PrPLP/Dpl) is neurotoxic. A line of PrP-deficient mice, Ngsk Prnp0/0, ectopically expressing PrPLP/Dpl in neurons, exhibits late-onset ataxia because of Purkinje cell death that is prevented by a transgene encoding wild-type mouse PrP. To elucidate the mechanisms of neurodegeneration in these mice, we introduced five types of PrP transgene, namely one heterologous hamster, two mouse/hamster chimeric genes, and two mutants, each of which encoded PrP lacking residues 23–88 (MHM2.del23–88) or with E199K substitution (Mo.E199K), into Ngsk Prnp0/0 mice. Only MHM2.del23–88 failed to rescue the mice from the Purkinje cell death. The transgenic mice, MHM2.del23–88/Ngsk Prnp0/0, expressed several times more PrP than did wild-type (Prnp +/+) mice and PrPLP/Dpl at an equivalent level to Ngsk Prnp0/0 mice. Little difference was observed in the pathology and onset of ataxia between Ngsk Prnp0/0 and MHM2.del23–88/Ngsk Prnp0/0. No detergent-insoluble PrPLP/Dpl was detectable in the central nervous system of Ngsk Prnp0/0 mice even after the onset of ataxia. Our findings provide evidence that the N-terminal residues 23–88 of PrP containing the unique octapeptide-repeat region is crucial for preventing Purkinje cell death in Prnp0/0 mice expressing PrPLP/Dpl in the neuron. Prion protein (PrP) 1The abbreviations used are: PrP, prion protein; PrPLP/Dpl, PrP-like protein/Doppel; SOD, superoxide dismutase; Gpx, glutathione peroxidase; Mo., mouse; Tg, transgenic. is a membrane glycoprotein expressed on the neuronal cell surface, but its physiological function is not fully understood. However, the complete resistance of PrP-deficient mice to prion infection indicates an essential role in the development of prion diseases and replication of prion (1Bueler H. Aguzzi A. Sailer A. Greiner R.A. Autenried P. Aguet M. Weissmann C. Cell. 1993; 73: 1339-1347Abstract Full Text PDF PubMed Scopus (1814) Google Scholar, 2Sakaguchi S. Katamine S. Shigematsu K. Nakatani A. Moriuchi R. Nishida N. Kurokawa K. Nakaoke R. Sato H. Jishage K. et al.J. Virol. 1995; 69: 7586-7592Crossref PubMed Google Scholar). In affected brains, the constitutive structural conversion of PrP results in the accumulation of a detergent-insoluble and proteinase K-resistant PrP isoform, namely PrPSc (3Prusiner S.B. Scott M.R. DeArmond S.J. Cohen F.E. Cell. 1998; 93: 337-348Abstract Full Text Full Text PDF PubMed Scopus (831) Google Scholar). Although accumulated PrPSc is thought to play a central role in the pathogenesis, molecular mechanisms for the neurodegeneration in prion diseases remain to be elucidated. We previously established a line of PrP-deficient mice, designated Ngsk Prnp0 /0, that exhibited late-onset ataxia because of cerebellar Purkinje cell degeneration (4Sakaguchi S. Katamine S. Nishida N. Moriuchi R. Shigematsu K. Sugimoto T. Nakatani A. Kataoka Y. Houtani T. Shirabe S. Okada H. Hasegawa S. Miyamoto T. Noda T. Nature. 1996; 380: 528-531Crossref PubMed Scopus (430) Google Scholar), which was rescued by the mouse wild-type PrP gene (Prnp) (5Nishida N. Tremblay P. Sugimoto T. Shigematsu K. Shirabe S. Petromilli C. Erpel S.P. Nakaoke R. Atarashi R. Houtani T. Torchia M. Sakaguchi S. DeArmond S.J. Prusiner S.B. Katamine S. Lab. Invest. 1999; 79: 689-697PubMed Google Scholar). Subsequently, these results were reproduced in two independent lines, Rcm0 and Zrch II Prnp0 /0 mice (6Moore R.C. Lee I.Y. Silverman G.L. Harrison P.M. Strome R. Heinrich C. Karunaratne A. Pasternak S.H. Chishti M.A. Liang Y. Mastrangelo P. Wang K. Smit A.F. Katamine S. Carlson G.A. Cohen F.E. Prusiner S.B. Melton D.W. Tremblay P. Hood L.E. Westaway D. J. Mol. Biol. 1999; 292: 797-817Crossref PubMed Scopus (474) Google Scholar, 7Rossi D. Cozzio A. Flechsig E. Klein M.A. Rulicke T. Aguzzi A. Weissmann C. EMBO J. 2001; 20: 694-702Crossref PubMed Scopus (225) Google Scholar). In contrast, two other independent lines, Zrch I and Edbg Prnp0 /0, have never revealed such a phenotype (8Bueler H. Fischer M. Lang Y. Bluethmann H. Lipp H.P. DeArmond S.J. Prusiner S.B. Aguet M. Weissmann C. Nature. 1992; 356: 577-582Crossref PubMed Scopus (1441) Google Scholar, 9Manson J.C. Clarke A.R. Hooper M.L. Aitchison L. McConnell I. Hope J. Mol. Neurobiol. 1994; 8: 121-127Crossref PubMed Scopus (498) Google Scholar). Recent studies have provided evidence that the ectopic expression of a PrP-like protein/Doppel (PrPLP/Dpl) in the neuron of ataxic Prnp0 /0 mouse lines but not non-ataxic lines could explain the discrepancy between phenotypes (6Moore R.C. Lee I.Y. Silverman G.L. Harrison P.M. Strome R. Heinrich C. Karunaratne A. Pasternak S.H. Chishti M.A. Liang Y. Mastrangelo P. Wang K. Smit A.F. Katamine S. Carlson G.A. Cohen F.E. Prusiner S.B. Melton D.W. Tremblay P. Hood L.E. Westaway D. J. Mol. Biol. 1999; 292: 797-817Crossref PubMed Scopus (474) Google Scholar, 10Li A. Sakaguchi S. Atarashi R. Roy B.C. Nakaoke R. Arima K. Okimura N. Kopacek J. Shigematsu K. Cell. Mol. Neurobiol. 2000; 20: 553-567Crossref PubMed Scopus (64) Google Scholar). Disruption of a part of the Prnp intron 2, including its splicing acceptor, in all the ataxic lines leads to unusual intergenic splicing between Prnp and the downstream gene, designated Prnd, encoding PrPLP/Dpl. As a consequence, the PrPLP/Dpl gene comes under the control of the Prnp promoter, leading to the ectopic expression of PrPLP/Dpl in the neuron. In the physiological situation, PrPLP/Dpl mRNA is expressed at a high level in the testis and heart but is not detectable in the brain except for transient expression by brain endothelial cells around 1 week after birth (11Li A. Sakaguchi S. Shigematsu K. Atarashi R. Roy B.C. Nakaoke R. Arima K. Okimura N. Kopacek J. Katamine S. Am. J. Pathol. 2000; 157: 1447-1452Abstract Full Text Full Text PDF PubMed Scopus (77) Google Scholar). A study using PrPLP/Dpl-deficient mice has suggested a physiological role for PrPLP/Dpl in spermatogenesis (12Behrens A. Genoud N. Naumann H. Rulicke T. Janett F. Heppner F.L. Ledermann B. Aguzzi A. EMBO J. 2002; 21: 3652-3658Crossref PubMed Scopus (138) Google Scholar). Recent reports demonstrated that introduction of a transgene encoding PrPLP/Dpl rendered Zrch I Prnp0 /0 mice capable of reproducing the Purkinje cell degeneration observed in the Ngsk Prnp0 /0 mice (13Moore R.C. Mastrangelo P. Bouzamondo E. Heinrich C. Legname G. Prusiner S.B. Hood L. Westaway D. DeArmond S.J. Tremblay P. Proc. Natl. Acad. of Sci. U. S. A. 2001; 98: 15288-15293Crossref PubMed Scopus (132) Google Scholar). This is direct evidence confirming that both ectopic expression of PrPLP/Dpl and functional loss of PrP are required for the neurodegeneration in Ngsk Prnp0 /0 mice. PrPLP/Dpl, a glycoprotein expressed on the cell surface with a glycosylphosphatidylinositol moiety (14Silverman G.L. Qin K. Moore R.C. Yang Y. Mastrangelo P. Tremblay P. Prusiner S.B. Cohen F.E. Westaway D. J. Biol. Chem. 2000; 275: 26834-26841Abstract Full Text Full Text PDF PubMed Google Scholar), consists of 179 amino acids with 23% identity to PrP in the primary structure but lacking the unique octapeptide-repeat region and hydrophobic region present in the N-terminal half of PrP (10Li A. Sakaguchi S. Atarashi R. Roy B.C. Nakaoke R. Arima K. Okimura N. Kopacek J. Shigematsu K. Cell. Mol. Neurobiol. 2000; 20: 553-567Crossref PubMed Scopus (64) Google Scholar). An NMR study revealed similarities in the tertiary structure between PrPLP/Dpl and the C-terminal half of PrP, both of which are composed of two short β-strands and three α-helices (15Mo H. Moore R.C. Cohen F.E. Westaway D. Prusiner S.B. Wright P.E. Dyson H.J. Proc. Natl. Acad. of Sci. U. S. A. 2001; 98: 2352-2357Crossref PubMed Scopus (141) Google Scholar). Interestingly, expression of a transgene encoding truncated PrP lacking N-terminal residues 32–121 or 32–134 in nonataxic Zrch I Prnp0 /0 mice also resulted in severe cerebellar degeneration, which was abrogated by reintroduction of the wild-type mouse PrP gene (16Shmerling D. Hegyi I. Fischer M. Blattler T. Brandner S. Gotz J. Rulicke T. Flechsig E. Cozzio A. von Mering C. Hangartner C. Aguzzi A. Weissmann C. Cell. 1998; 93: 203-214Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar). These results have suggested that PrPLP/Dpl and N-terminal-truncated (del32–121 or 32–134) PrP are toxic to neurons through similar mechanisms and that wild-type PrP may have a neuroprotective function. In the present study, to further elucidate mechanisms of the Purkinje cell death, we generated five different transgenic mouse lines expressing, respectively, heterologous, chimeric, and mutant PrPs on the Ngsk Prnp0 /0 background. A transgene encoding PrP-lacking N-terminal residues 23–88 failed to rescue the Ngsk Prnp0 /0 mice from Purkinje cell degeneration, indicating a crucial role for the residues. The roles of PrPLP/Dpl aggregation and impaired metabolism of reactive oxygen species in the brain tissues of Ngsk Prnp0 /0 mice were also evaluated. Mice—The mouse PrP (Mo.PrP) transgenic (Tg) mice with the Ngsk Prnp0 /0 background were as described previously (5Nishida N. Tremblay P. Sugimoto T. Shigematsu K. Shirabe S. Petromilli C. Erpel S.P. Nakaoke R. Atarashi R. Houtani T. Torchia M. Sakaguchi S. DeArmond S.J. Prusiner S.B. Katamine S. Lab. Invest. 1999; 79: 689-697PubMed Google Scholar). In the current study, we introduced five types of PrP transgene into Ngsk Prnp0 /0 mice by mating them with the transgenic mouse lines, each harboring the corresponding transgene with the Zrch I Prnp0 /0 background (8Bueler H. Fischer M. Lang Y. Bluethmann H. Lipp H.P. DeArmond S.J. Prusiner S.B. Aguet M. Weissmann C. Nature. 1992; 356: 577-582Crossref PubMed Scopus (1441) Google Scholar). Drs. P. Tremblay and S. B. Prusiner, University of California, San Francisco, CA kindly provided the Tg mouse lines. The transgenes included a Syrian hamster wild-type PrP gene (SHa); two SHa/mouse chimeric PrP genes (MH2M and MHM2), MHM2 lacking residues 23 to 88 (MHM2.del23–88); and Mo.PrP gene with E199K substitution (Mo.E199K) (17Scott M. Foster D. Mirenda C. Serban D. Coufal F. Walchli M. Torchia M. Groth D. Carlson G. DeArmond S.J. et al.Cell. 1989; 59: 847-857Abstract Full Text PDF PubMed Scopus (583) Google Scholar, 18Scott M. Groth D. Foster D. Torchia M. Yang S.L. DeArmond S.J. Prusiner S.B. Cell. 1993; 73: 979-988Abstract Full Text PDF PubMed Scopus (272) Google Scholar, 19Supattapone S. Bosque P. Muramoto T. Wille H. Aagaard C. Peretz D. Nguyen H.O. Heinrich C. Torchia M. Safar J. Cohen F.E. DeArmond S.J. Prusiner S.B. Scott M. Cell. 1999; 96: 869-878Abstract Full Text Full Text PDF PubMed Scopus (193) Google Scholar, 20Telling G.C. Haga T. Torchia M. Tremblay P. DeArmond S.J. Prusiner S.B. Genes Dev. 1996; 10: 1736-1750Crossref PubMed Scopus (238) Google Scholar). They were constructed in a cosSHa.Tet. vector, encompassing the entire SHa Prnp locus but not containing the PrPLP/Dpl locus (Prnd) (6Moore R.C. Lee I.Y. Silverman G.L. Harrison P.M. Strome R. Heinrich C. Karunaratne A. Pasternak S.H. Chishti M.A. Liang Y. Mastrangelo P. Wang K. Smit A.F. Katamine S. Carlson G.A. Cohen F.E. Prusiner S.B. Melton D.W. Tremblay P. Hood L.E. Westaway D. J. Mol. Biol. 1999; 292: 797-817Crossref PubMed Scopus (474) Google Scholar). MHM2 PrP has two amino acid substitutions from Mo.PrP, L108M and V111M, which are included in the epitope recognized by 3F4 anti-PrP antibody. MH2M PrP has five amino acid substitutions (L108M, V111M, I138M, Y154N, and S169N) from Mo.PrP. The E199K substitution in Mo.E199K PrP corresponds to that found in patients with familial Creutzfeldt-Jakob disease (21Hsiao K. Meiner Z. Kahana E. Cass C. Kahana I. Avrahami D. Scarlato G. Abramsky O. Prusiner S.B. Gabizon R. N. Engl. J. Med. 1991; 324: 1091-1097Crossref PubMed Scopus (226) Google Scholar). Offspring carrying the transgenes were identified by PCR of tail DNA as described previously (5Nishida N. Tremblay P. Sugimoto T. Shigematsu K. Shirabe S. Petromilli C. Erpel S.P. Nakaoke R. Atarashi R. Houtani T. Torchia M. Sakaguchi S. DeArmond S.J. Prusiner S.B. Katamine S. Lab. Invest. 1999; 79: 689-697PubMed Google Scholar). To distinguish Ngsk from Zrch I Prnp0 /0 genotypes, both a Zrch I-specific primer pair (MP685S, 5′-AACTTCACCGAGACCGATGT and MP215A, 5′-GAACCCTTTGCCTATGCTAA) and a Ngsk-specific primer pair (PGK468S, 5′-CGCTGTTCTCCTCTTCCTCA and NEO390A, 5′-GGTAGCCGGATCAAGCGTAT) were used in the PCR. The F2 offspring carrying transgenes with Ngsk Prnp0 /0 background, Tg/Ngsk Prnp0 /0, were subjected to analysis. Antibodies—The anti-PrP polyclonal mouse antiserum used was described previously (5Nishida N. Tremblay P. Sugimoto T. Shigematsu K. Shirabe S. Petromilli C. Erpel S.P. Nakaoke R. Atarashi R. Houtani T. Torchia M. Sakaguchi S. DeArmond S.J. Prusiner S.B. Katamine S. Lab. Invest. 1999; 79: 689-697PubMed Google Scholar). We produced anti-PrPLP/Dpl polyclonal rabbit antiserum using full-length (27–155) recombinant mouse PrPLP/Dpl. 3F4 anti-PrP antibody was purchased from Dako. SAF-mix antibody was a kind gift from Dr. S. Lehmann (22Nishida N. Harris D.A. Vilette D. Laude H. Frobert Y. Grassi J. Casanova D. Milhavet O. Lehmann S. J. Virol. 2000; 74: 320-325Crossref PubMed Scopus (215) Google Scholar). Horseradish peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG antibodies were purchased from Amersham Biosciences. Western Blotting—Brain homogenates (10%, w/v) were prepared in a lysis buffer containing 150 mm NaCl, 50 mm Tris-HCl (pH 7.5), 0.5% Triton X-100, 0.5% sodium deoxycholate, 1 mm EDTA, and protease inhibitor mixture (Roche Applied Science). Postnuclear supernatants were collected after low speed centrifugation, and protein concentrations were determined using the BCA protein assay (Pierce). Samples were electrophoresed through SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membrane (Millipore). Anti-PrP polyclonal mouse antiserum or anti-PrPLP/Dpl polyclonal rabbit antiserum was used as a probe, and immunoreactive bands were visualized using the ECL system (Amersham Biosciences). PNGase F Digestion—PNGase F digestion of brain homogenates was performed according to the manufacturer's protocol (New England Bio-labs). Briefly, glycoproteins of each sample were denatured by boiling for 10 min in 0.5% SDS and 1% β-mercaptoethanol. 110 volume of 10% Nonidet P-40, 110 volume of 0.5 m sodium phosphate (pH 7.5), and 2 μl of PNGase F (500 units/μl) were added to each sample. After incubation for 2 h at 37 °C, samples were subjected to Western blotting analysis. Detergent Insolubility of PrPLP/Dpl—Postnuclear supernatants were diluted to a 4 mg/ml protein concentration in the lysis buffer with or without Sarcosyl (1% final concentration). After incubation on ice for 30 min, samples were centrifuged at 108,000 × g for 45 min at 4 °C. Proteins in the pellets and supernatant were analyzed by Western blotting. Immunohistochemistry—Deparaffinized sections were digested with 1 mg/ml trypsin for 15 min at 37 °C and then placed in 3% H2O2 in methanol for 30 min at room temperature to abolish endogenous peroxidase activity. The tissue sections were incubated overnight at 4 °C with anti-spot 35 (calbindin) polyclonal antibody. To detect spot 35 immunoreactivities, we used the EnVision+, in accordance with the manufacturer's recommendations (Dako). The antibody-bound peroxidase was revealed with 0.04% diaminobenzidine (Sigma). Superoxide Dismutase (SOD) and Glutathione Peroxidase (Gpx) Activities—Brain homogenates were prepared in phosphate-buffered saline containing 1 mm EDTA and protease inhibitor mixture (Roche Applied Science). Homogenates were centrifuged at 10,000 × g for 10 min, and supernatants were subjected to analysis. The protein concentration of the supernatants was determined using the BCA protein assay (Pierce). The total SOD activity was measured by inhibition of the reduction rate of nitro blue tetrazolium, monitored at 560 nm using xanthine and the xanthine oxidase system. One unit of SOD activity was defined as the amount of the enzyme required to inhibit the reduction rate of nitro blue tetrazolium by 50%. The activity was expressed as units/mg of protein. To measure Mn-SOD activity, the reaction mixture was treated with 2 mm potassium cyanide. To obtain Cu/Zn-SOD activity, the amount of Mn-SOD activity was subtracted from the total SOD activity. The Gpx activity was measured by determining the rate of NADPH oxidation to NADP, monitored at 340 nm using glutathione reductase and the NADPH system. The activity was expressed as nmol/min/mg of protein. Rescue of Ngsk Prnp0 / 0 Mice from Neurodegeneration by Mo.E199K but Not MHM2.del23–88 PrP Mutants—We introduced five types of PrP transgene (SHa, MH2M, MHM2, MHM2.del23–88, and Mo.E199K) into Ngsk Prnp0 /0 and evaluated their effects on the phenotype. All the Tg/Ngsk Prnp0 /0 mice developed normally and initially showed no neurological symptoms. At about 13 months after birth, however, Tg-MHM2.del23–88/Ngsk Prnp0 /0 mice, as well as Ngsk Prnp0 /0 mice lacking a PrP transgene, began to exhibit progressive symptoms of ataxia, such as tremor and gait disturbance (Fig. 1A). Analysis of hind footprints confirmed that the ataxic mice could not walk in a straight line, and the length of their steps was shorter than that of the wild-type mice (Fig. 1B). Age at onset of Ngsk Prnp0 /0 and Tg-MHM2.del23–88/Ngsk Prnp0 /0 mice were 68.4 ± 5.6 and 67.0 ± 6.5 weeks (mean ± S.D.), respectively. The remaining Tg/Ngsk Prnp0 /0 lines have never shown any neurological symptoms up to 24 months of age, indicating that SHa, MH2M, MHM2, and MoE199K transgenes, but not MHM2.del23–88, were able to rescue the Ngsk Prnp0 /0 mice from ataxia. Immunostaining with anti-spot 35 (calbindin) antibody of the brain sections derived from 20-month-old Ngsk Prnp0 /0 and Tg-MHM2.del23–88/Ngsk Prnp0 /0 mice revealed an extensive loss of Purkinje cells throughout most of the cerebellar vermis (Fig. 2, B and G). No difference was found in the extent of Purkinje cell loss between the two mouse lines. In contrast, the Tg-SHa, Tg-MH2M, Tg-MHM2, and Tg-Mo.E199K/Ngsk Prnp0 /0 mice showed no Purkinje cell loss (Fig. 2, A, C, D, E, and F). Expression of Transgene-encoded PrP in the Brain Tissues of Tg/Ngsk Prnp0 / 0 Mouse Lines—Expression of the transgene products, PrPs, in the brain tissues of 4-month-old Tg mice was examined by Western blotting using polyclonal anti-PrP mouse serum (Fig. 3) and SAF-mix anti-PrP monoclonal antibody (data not shown). Two lines, Tg-MHM2 and Tg-MHM2.del23–88/Ngsk Prnp0 /0, overexpressed PrP about four to eight times more than wild-type mice. The expression levels of the remaining three, Tg-SHa, Tg-MH2M, and Tg-Mo.E199K/Ngsk Prnp0 /0, appeared to be equivalent to that of wild-type mice. As shown in Fig. 4A, after deglycosylation by PNGase F, SAF-mix visualized two clear bands of 18 and 27 kDa and a faint band of 21 kDa in the brain homogenates from Tg-SHa and Tg-MHM2/Ngsk Prnp0 /0 mice, but 3F4 monoclonal antibody failed to detect an 18-kDa product (Fig. 4B). It has been demonstrated that PrPC undergoes physiological proteolytic cleavage at amino acid residues 110/111 or 111/112, leading to the production of a C-terminal fragment, C1 (23Chen S.G. Teplow D.B. Parchi P. Teller J.K. Gambetti P. Autilio-Gambetti L. J. Biol. Chem. 1995; 270: 19173-19180Abstract Full Text Full Text PDF PubMed Scopus (453) Google Scholar). Because the cleavage occurs within the linear 3F4 epitope, C1 is recognized by SAF-mix but not by 3F4. The 18-kDa band is thus most likely to correspond to C1. The remaining 27- and 21-kDa bands are likely to be the full-length PrP and another C-terminal minor product, C2, respectively. The brain tissues from MHM2.del23–88/Ngsk Prnp0 /0 mice also expressed an 18-kDa band that reacted with SAF-mix but not 3F4, in addition to its full-length product of 20 kDa (lane 6 in Fig. 4, A and B). Expression Levels and Detergent Insolubility of PrPLP/Dpl in the Brain Tissues of Tg/Ngsk Prnp0 / 0 Mouse Lines—PrPLP/Dpl expression levels in the brains were examined by Western blotting with polyclonal anti-PrPLP/Dpl rabbit antiserum. Although the brain tissues of Prnp +/+ mice expressed no detectable PrPLP/Dpl, the Tg/Ngsk Prnp0 /0 mouse lines all exhibited PrPLP/Dpl expression at levels equivalent to those of Ngsk Prnp0 /0 mice (Fig. 5). The expression levels remained stable during aging, even after the onset of ataxia (data not shown). Accumulating evidence has indicated that certain neurodegenerative conditions are caused by aggregation of detergent-insoluble proteins, such as PrPSc, in the central nervous system (24Murphy R.M. Annu. Rev. Biomed. Eng. 2002; 4: 155-174Crossref PubMed Scopus (206) Google Scholar). To evaluate the possibility of PrPLP/Dpl aggregation in the brain tissues, we examined the detergent-insolubility of PrPLP/Dpl in the brains of ataxic Ngsk Prnp0 /0 and Tg-SHa/Ngsk Prnp0 /0 mice at 98 weeks of age. As shown in Fig. 6A, PrPLP/Dpl was partially insoluble in the buffer containing 0.5% Triton X-100 and 0.5% sodium deoxycholate but completely solubilized by 1% sarcosyl. The levels of Triton X-100-insoluble fraction of PrPLP/Dpl were similar between Ngsk Prnp0 /0 and Tg-SHa/Ngsk Prnp0 /0 mice even at 98 weeks of age and did not increase during aging (Fig. 6B). SOD and Gpx Activities in the Brain Tissues of Ngsk Prnp0 / 0 Mice Are Not Reduced—Finally, the possible involvement of the down-regulation of anti-oxidative enzyme activities in the neurodegeneration in Ngsk Prnp0 /0 mice was evaluated. The activities of SOD and Gpx in the brain tissues of Ngsk Prnp0 /0 mice at 6 months of age were measured and compared with those of two age-matched control mouse lines, Prnp +/+and Tg-Mo.PrP/Ngsk Prnp0 /0. Cu/Zn-SOD activities of Prnp +/+, Ngsk Prnp0 /0, and Tg-Mo.PrP/Ngsk Prnp0 /0 mice were 169.2 ± 3.1, 182.8 ± 14.9, and 183.4 ± 10.5 units/mg protein (mean ± S.D.), respectively, and Mn-SOD activities were 19.8 ± 2.3, 19.2 ± 2.7, and 18.2 ± 0.4 units/mg protein, respectively (Fig. 7A). There was no statistically significant difference. Gpx activities were also similar among the mouse lines: 67.1 ± 4.8, 63.7 ± 5.3, and 62.9 ± 0.8 nmol/min/mg protein, respectively (Fig. 7B). We previously demonstrated that wild-type Mo.PrP has the potential to prevent PrPLP/Dpl-induced neurodegeneration in Ngsk Prnp0 /0 mice (5Nishida N. Tremblay P. Sugimoto T. Shigematsu K. Shirabe S. Petromilli C. Erpel S.P. Nakaoke R. Atarashi R. Houtani T. Torchia M. Sakaguchi S. DeArmond S.J. Prusiner S.B. Katamine S. Lab. Invest. 1999; 79: 689-697PubMed Google Scholar). The present study showed that Mo.E199K PrP, as well as heterologous hamster and hamster/mouse chimeric PrPs, but not MHM2.del23–88 PrP, could rescue Ngsk Prnp0 /0 mice from Purkinje cell death. Mo.E199K represents the E200K substitution in human PrP, which is commonly found in patients with familial Creutzfeldt-Jakob disease (21Hsiao K. Meiner Z. Kahana E. Cass C. Kahana I. Avrahami D. Scarlato G. Abramsky O. Prusiner S.B. Gabizon R. N. Engl. J. Med. 1991; 324: 1091-1097Crossref PubMed Scopus (226) Google Scholar). The successful rescue by Mo.E199K strongly indicates that the mutant retains the major aspects of normal PrP function and thus argues against a dominant-negative role for the mutant. The solution structure of recombinant human PrP 90–231 with E200K was reported to be nearly identical to that of wild-type PrP (25Zhang Y. Swietnicki W. Zagorski M.G. Surewicz W.K. Sonnichsen F.D. J. Biol. Chem. 2000; 275: 33650-33654Abstract Full Text Full Text PDF PubMed Scopus (117) Google Scholar). This finding also supports the notion that the amino acid substitution does not disrupt the structure critical for the normal function of PrP. Although various hypothetical models have been proposed, precise mechanisms for the neurodegeneration seen in Ngsk Prnp0 /0 mice remain to be elucidated. In addition to the structural similarities between PrP and PrPLP/Dpl, the previous finding that a recombinant C-terminal PrP (121–231) fragment could convert into a β-sheet-rich structure at acidic pH in vitro (26Hornemann S. Glockshuber R. Proc. Natl. Acad. of Sci. U. S. A. 1998; 95: 6010-6014Crossref PubMed Scopus (240) Google Scholar) prompted us to examine the involvement of abnormal PrPLP/Dpl aggregation in the neurodegeneration. However, we failed to detect detergent-insoluble PrPLP/Dpl accumulation in the central nervous system of Ngsk Prnp0 /0 mice even after the onset of ataxia. PrPLP/Dpl contains two intramolecular disulfide bonds at the C-terminal portion (14Silverman G.L. Qin K. Moore R.C. Yang Y. Mastrangelo P. Tremblay P. Prusiner S.B. Cohen F.E. Westaway D. J. Biol. Chem. 2000; 275: 26834-26841Abstract Full Text Full Text PDF PubMed Google Scholar), in contrast to PrP with a single disulfide bond, which has been shown to be necessary for conversion to the pathogenic isoform, PrPSc. The structures determined by intramolecular disulfide bonds may account for the difference between the two proteins in the potential for structural conversion. It is noteworthy that the MHM2.del23–88 transgene, which encoded a product lacking almost the entire unique octapeptide-repeat region, failed to rescue Ngsk Prnp0 /0 mice from neurodegeneration. Little difference was observed in the pathology and onset of ataxia between Ngsk Prnp0 /0 and Tg-MHM2.del23–88/Ngsk Prnp0 /0 mice. The PrP expression level of Tg-MHM2.del23–88/Ngsk Prnp0 /0 mice was higher than that of Tg-SHa and Tg-MH2M/Ngsk Prnp0 /0 but similar to that of Tg-MHM2/Ngsk Prnp0 /0 mice. This strongly indicates that the N-terminal part of PrP is essential to the rescue from Purkinje cell death. In contrast, MHM2.del23–88 PrP was shown to retain the potential to convert into the pathogenic isoform in prion-infected cell cultures (27Rogers M. Yehiely F. Scott M. Prusiner S.B. Proc. Natl. Acad. of Sci. U. S. A. 1993; 90: 3182-3186Crossref PubMed Scopus (158) Google Scholar) and brain tissues of Tg-MHM2.del23–88 mice (19Supattapone S. Bosque P. Muramoto T. Wille H. Aagaard C. Peretz D. Nguyen H.O. Heinrich C. Torchia M. Safar J. Cohen F.E. DeArmond S.J. Prusiner S.B. Scott M. Cell. 1999; 96: 869-878Abstract Full Text Full Text PDF PubMed Scopus (193) Google Scholar). The N-terminal region could thus be a key factor for determining whether physiological function is maintained but is likely to be less important in pathogenic structural conversion. Because the unique octapeptide-repeat region has the potential to bind copper (28Hornshaw M.P. McDermott J.R. Candy J.M. Biochem. Biophys. Res. Commun. 1995; 207: 621-629Crossref PubMed Scopus (323) Google Scholar), PrP may function in the transport or metabolism of copper in the neuron (29Brown D.R. Qin K. Herms J.W. Madlung A. Manson J. Strome R. Fraser P.E. Kruck T. von Bohlen A. Schulz-Schaeffer W. Giese A. Westaway D. Kretzschmar H. Nature. 1997; 390: 684-687Crossref PubMed Scopus (37) Google Scholar, 30Herms J. Tings T. Gall S. Madlung A. Giese A. Siebert H. Schurmann P. Windl O. Brose N. Kretzschmar H. J. Neurosci. 1999; 19: 8866-8875Crossref PubMed Google Scholar, 31Pauly P.C. Harris D.A. J. Biol. Chem. 1998; 273: 33107-33110Abstract Full Text Full Text PDF PubMed Scopus (543) Google Scholar). Copper is involved in various aspects of reactive oxygen species metabolism (32Linder M.C. Hazegh-Azam M. Am. J. Clin. Nutr. 1996; 63: 797S-811SPubMed Google Scholar). It could thus be possible that impaired copper transport may result in reactive oxygen species accumulation, leading to cell death. Indeed, the reduced activity of Cu/Zn-SOD in the brains of Zrch I Prnp0 /0 mice has been reported (33Brown D.R. Besinger A. Biochem. J. 1998; 334: 423-429Crossref PubMed Scopus (244) Google Scholar). However, along with other contradictory reports (34Waggoner D.J. Drisaldi B. Bartnikas T.B. Casareno R.L. Prohaska J.R. Gitlin J.D. Harris D.A. J. Biol. Chem. 2000; 275: 7455-7458Abstract Full Text Full Text PDF PubMed Scopus (170) Google Scholar), the present study failed to show reduced activities of Cu/Zn-SOD, Mn-SOD, and Gpx in the brains of Ngsk Prnp0 /0 mice. The fact that Cu/Zn-SOD-deficient mice have never developed any neurological signs such as ataxia (35Reaume A.G. Elliott J.L. Hoffman E.K. Kowall N.W. Ferrante R.J. Siwek D.F. Wilcox H.M. Flood D.G. Beal M.F. Brown Jr., R.H. Scott R.W. Snider W.D. Nat. Genet. 1996; 13: 43-47Crossref PubMed Scopus (1051) Google Scholar) also argues against a causal relationship between reduced activity of Cu/Zn-SOD and Purkinje cell death. Interestingly, Tg mice expressing PrP.del32–121 or 32–134 on the Zrch I Prnp0 /0 background also developed cerebellar cell death, but those with wild-type Prnp background did not (16Shmerling D. Hegyi I. Fischer M. Blattler T. Brandner S. Gotz J. Rulicke T. Flechsig E. Cozzio A. von Mering C. Hangartner C. Aguzzi A. Weissmann C. Cell. 1998; 93: 203-214Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar). The two mutant PrPs lack a part of or most of the hydrophobic region (111–134), in addition to the octapeptide-repeat region, which are also absent in PrPLP/Dpl. The structural similarities between PrP.del32–121/32–134 and PrPLP/Dpl strongly suggested that a common mechanism is involved in the neurodegeneration in the Tg mice and Ngsk Prnp0 /0 mice. Behrens and Aguzzi (36Behrens A. Aguzzi A. Trends Neurosci. 2002; 25: 150-154Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar) have hypothesized an as yet unidentified ligand, which harbors affinities to both PrP and PrPLP/Dpl or the N terminus-truncated PrPs. In the absence of PrP, binding of the putative ligand to PrPLP/Dpl or PrP.del32–121/32–134 may trigger an apoptotic signal or prevent a survival signal. On the other hand, in the presence of PrP, the binding would be impeded because of much lower affinity. If this is the case, the failure of MHM2.del23–88 PrP in the phenotype rescue suggests that residues 23–88 include a site critical for ligand binding or functional transduction of ligand signals. Recent studies have demonstrated that copper binds not only to the octapeptide-repeat region but also to the C-terminal PrP-(91–231/121–231) fragments (37Cereghetti G.M. Schweiger A. Glockshuber R. Van Doorslaer S. Biophys. J. 2001; 81: 516-525Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar, 38Jackson G.S. Murray I. Hosszu L.L. Gibbs N. Waltho J.P. Clarke A.R. Collinge J. Proc. Natl. Acad. of Sci. U. S. A. 2001; 98: 8531-8535Crossref PubMed Scopus (458) Google Scholar) and PrPLP/Dpl (39Qin K. Coomaraswamy J. Mastrangelo P. Yang Y. Lugowski S. Petromilli C. Prusiner S.B. Fraser P.E. Goldberg J.M. Chakrabartty A. Westaway D. J. Biol. Chem. 2003; 278: 8888-8896Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar). Hence, copper could be one candidate for this hypothetical ligand, acting to raise a neurotoxic signal or prevent a survival signal through binding to PrPLP/Dpl or PrP.del32–121/32–134. We demonstrated that MHM2.del23–88 PrP, as well as full-length PrP, underwent proteolytic cleavage leading to the production of C1. This indicated that loss of the N-terminal residues 23–88 did not affect the cleavage, and C1 was not necessary for the phenotype rescue. It has also been shown that a N-terminal cleavage product, PrP-(23–110/111), designated N1, was released into the supernatant of cultured cells (40Vincent B. Paitel E. Frobert Y. Lehmann S. Grassi J. Checler F. J. Biol. Chem. 2000; 275: 35612-35616Abstract Full Text Full Text PDF PubMed Scopus (102) Google Scholar). An intriguing hypothesis is that N1 may play a neuroprotective role outside of the cells. For instance, it may bind to copper or other molecules to produce a neuroprotective signal. The N1 derived from MHM2.del23–88 PrP lacking the octapeptide-repeat region is unlikely to preserve this function. It would be of value to examine the potential of N1 to rescue Ngsk Prnp0 /0 mice from the Purkinje cell death. Another model for the neurodegeneration to be evaluated is that the absence of PrP might make cerebellar cells vulnerable to a constitutive weak apoptotic signal transduced by PrPLP/Dpl (36Behrens A. Aguzzi A. Trends Neurosci. 2002; 25: 150-154Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar). PrP could raise an anti-apoptotic signal independently and protect from the PrPLP/Dpl-induced apoptosis. Accumulating evidence has supported an anti-apoptotic role of PrP. For instance, overexpression of PrP protected human primary neurons from Bax-mediated apoptosis (41Bounhar Y. Zhang Y. Goodyer C.G. LeBlanc A. J. Biol. Chem. 2001; 276: 39145-39149Abstract Full Text Full Text PDF PubMed Scopus (305) Google Scholar). The protective effect was abolished by deletion of the octapeptide-repeat region, residues 56–88, of human PrP. Serum withdrawal-induced apoptosis of immortalized hippocampal cells derived from Prnp0 /0 mice was also prevented by overexpressed PrP or Bcl-2 (42Kuwahara C. Takeuchi A.M. Nishimura T. Haraguchi K. Kubosaki A. Matsumoto Y. Saeki K. Yokoyama T. Itohara S. Onodera T. Nature. 1999; 400: 225-226Crossref PubMed Scopus (374) Google Scholar). Chiarini et al. (43Chiarini L.B. Freitas A.R. Zanata S.M. Brentani R.R. Martins V.R. Linden R. EMBO J. 2002; 21: 3317-3326Crossref PubMed Scopus (304) Google Scholar) recently demonstrated evidence that a peptide capable of binding to residues 113–128 of PrP protected developing retina neurons from apoptosis via activation of cAMP-dependent protein kinase. The same group has identified stress-inducible protein 1, a heat-shock protein, which binds residues 113–128 of PrP and promotes a neuroprotective signal (44Zanata S.M. Lopes M.H. Mercadante A.F. Hajj G.N. Chiarini L.B. Nomizo R. Freitas A.R. Cabral A.L. Lee K.S. Juliano M.A. de Oliveira E. Jachieri S.G. Burlingame A. Huang L. Linden R. Brentani R.R. Martins V.R. EMBO J. 2002; 21: 3307-3316Crossref PubMed Scopus (371) Google Scholar). Interestingly, expression of PrP.del32–121/32–134 in Zrch I Prnp0 /0 mice induced cerebellar neurodegeneration, but MHM2.del23–88 PrP preserving residues 113–128 did not. The absence of the potential to bind to stress-inducible protein 1 may be crucial for the neurotoxic effects of PrP.del32–121/32–134 and PrPLP/Dpl. In prion diseases, the constitutive conversion of PrP into the pathogenic isoform, PrPSc, is likely to result in the functional loss of normal PrP (45Yokoyama T. Kimura K.M. Ushiki Y. Yamada S. Morooka A. Nakashiba T. Sassa T. Itohara S. J. Biol. Chem. 2001; 276: 11265-11271Abstract Full Text Full Text PDF PubMed Scopus (104) Google Scholar). If PrPSc mimics the neurotoxic role of PrPLP/Dpl or PrP.del32–121/32–134, Ngsk Prnp0 /0 mice lacking PrP but ectopically expressing PrPLP/Dpl in neurons could be a valuable model for the neurodegeneration. Alternatively, it is also possible that the mechanisms of neurodegeneration in mice are distinct from those of prion diseases, based on the present finding that no detergent-insoluble PrPLP/Dpl was detectable in mouse brain tissues. Elucidation of the molecular mechanisms responsible for the neurodegeneration in Ngsk Prnp0 /0 mice would provide new insights into the understanding of the pathogenesis of prion diseases and other neurodegenerative conditions, as well as the physiological function of PrP. We are grateful to Drs. Stanley B. Prusiner, Patrick Tremblay, and Sylvain Lehmann for providing mice and reagents. We thank Nobuhiko Okimura for technical support, Aimin Li for the anti-PrPLP/Dpl polyclonal rabbit antiserum, and Amanda Nishida for help in preparation of the manuscript." @default.
• W2000603962 created "2016-06-24" @default.
• W2000603962 creator A5020639857 @default.
• W2000603962 creator A5022510364 @default.
• W2000603962 creator A5031516587 @default.
• W2000603962 creator A5036745181 @default.
• W2000603962 creator A5053812257 @default.
• W2000603962 creator A5066969352 @default.
• W2000603962 creator A5085135960 @default.
• W2000603962 date "2003-08-01" @default.
• W2000603962 modified "2023-09-29" @default.
• W2000603962 title "Deletion of N-terminal Residues 23–88 from Prion Protein (PrP) Abrogates the Potential to Rescue PrP-deficient Mice from PrP-like Protein/Doppel-induced Neurodegeneration" @default.
• W2000603962 cites W1549404680 @default.
• W2000603962 cites W1550540174 @default.
• W2000603962 cites W1665321266 @default.
• W2000603962 cites W1704732331 @default.
• W2000603962 cites W1974764248 @default.
• W2000603962 cites W1979695510 @default.
• W2000603962 cites W1992380356 @default.
• W2000603962 cites W1994052479 @default.
• W2000603962 cites W2003681781 @default.
• W2000603962 cites W2006810449 @default.
• W2000603962 cites W2012109320 @default.
• W2000603962 cites W2012128918 @default.
• W2000603962 cites W2017634178 @default.
• W2000603962 cites W2021489997 @default.
• W2000603962 cites W2027907160 @default.
• W2000603962 cites W2029162694 @default.
• W2000603962 cites W2029246626 @default.
• W2000603962 cites W2036675767 @default.
• W2000603962 cites W2041442366 @default.
• W2000603962 cites W2042978244 @default.
• W2000603962 cites W2067417543 @default.
• W2000603962 cites W2072978915 @default.
• W2000603962 cites W2077657292 @default.
• W2000603962 cites W2082872027 @default.
• W2000603962 cites W2087174680 @default.
• W2000603962 cites W2096510701 @default.
• W2000603962 cites W2099437683 @default.
• W2000603962 cites W2105691290 @default.
• W2000603962 cites W2106235316 @default.
• W2000603962 cites W2108180175 @default.
• W2000603962 cites W2119616506 @default.
• W2000603962 cites W2121611717 @default.
• W2000603962 cites W2128057594 @default.
• W2000603962 cites W2132661882 @default.
• W2000603962 cites W2138163763 @default.
• W2000603962 cites W2147276565 @default.
• W2000603962 cites W2147592113 @default.
• W2000603962 cites W2147987476 @default.
• W2000603962 cites W2149247478 @default.
• W2000603962 cites W2152958744 @default.
• W2000603962 cites W2340182873 @default.
• W2000603962 cites W3119478644 @default.
• W2000603962 cites W329392657 @default.
• W2000603962 doi "https://doi.org/10.1074/jbc.m303655200" @default.
• W2000603962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12759361" @default.
• W2000603962 hasPublicationYear "2003" @default.
• W2000603962 type Work @default.
• W2000603962 sameAs 2000603962 @default.
• W2000603962 citedByCount "47" @default.
• W2000603962 countsByYear W20006039622012 @default.
• W2000603962 countsByYear W20006039622013 @default.
• W2000603962 countsByYear W20006039622014 @default.
• W2000603962 countsByYear W20006039622015 @default.
• W2000603962 crossrefType "journal-article" @default.
• W2000603962 hasAuthorship W2000603962A5020639857 @default.
• W2000603962 hasAuthorship W2000603962A5022510364 @default.
• W2000603962 hasAuthorship W2000603962A5031516587 @default.
• W2000603962 hasAuthorship W2000603962A5036745181 @default.
• W2000603962 hasAuthorship W2000603962A5053812257 @default.
• W2000603962 hasAuthorship W2000603962A5066969352 @default.
• W2000603962 hasAuthorship W2000603962A5085135960 @default.
• W2000603962 hasBestOaLocation W20006039621 @default.
• W2000603962 hasConcept C142724271 @default.
• W2000603962 hasConcept C153911025 @default.
• W2000603962 hasConcept C159047783 @default.
• W2000603962 hasConcept C185592680 @default.
• W2000603962 hasConcept C2776925932 @default.
• W2000603962 hasConcept C2779134260 @default.
• W2000603962 hasConcept C2779664074 @default.
• W2000603962 hasConcept C3019804061 @default.
• W2000603962 hasConcept C41008148 @default.
• W2000603962 hasConcept C55493867 @default.
• W2000603962 hasConcept C71924100 @default.
• W2000603962 hasConcept C76155785 @default.
• W2000603962 hasConcept C86803240 @default.
• W2000603962 hasConcept C95444343 @default.
• W2000603962 hasConceptScore W2000603962C142724271 @default.
• W2000603962 hasConceptScore W2000603962C153911025 @default.
• W2000603962 hasConceptScore W2000603962C159047783 @default.
• W2000603962 hasConceptScore W2000603962C185592680 @default.
• W2000603962 hasConceptScore W2000603962C2776925932 @default.
• W2000603962 hasConceptScore W2000603962C2779134260 @default.
• W2000603962 hasConceptScore W2000603962C2779664074 @default.
• W2000603962 hasConceptScore W2000603962C3019804061 @default.
• W2000603962 hasConceptScore W2000603962C41008148 @default.
• W2000603962 hasConceptScore W2000603962C55493867 @default.

• next